D'Souza Deborah N, Zhang Yahong, Damjanoska Katerina J, Carrasco Gonzalo A, Sullivan Nicole R, Garcia Francisca, Battaglia George, Doncarlos Lydia L, Muma Nancy A, Van de Kar Louis D
Center for Serotonin Disorders Research, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA.
Neuroendocrinology. 2004;80(1):31-41. doi: 10.1159/000080795.
The present study examined the effect of estradiol on hypothalamic serotonin-1A (5-HT(1A)) receptor signaling in female rats. We first examined the time-course effects of a single injection of the 5-HT(1A) receptor agonist (+/-)8-OH-DPAT (5, 15 or 30 min prior to decapitation), and dose response of (+)8-OH-DPAT (50, 100, 200 or 500 microg/kg, s.c.) on plasma hormones in ovariectomized rats that received a daily injection of beta-estradiol 3-benzoate (10 microg/day, s.c.) or vehicle (sesame oil) for 2 days. In vehicle- and estrogen-treated rats, the peak response of hormones occurred at 15 min after injection and the time-course of oxytocin and adrenocorticotropic hormone (ACTH) responses to an injection of 8-OH-DPAT were comparable. However, only the oxytocin response was reduced by estrogen treatment. A second experiment compared the ACTH and oxytocin responses with doses of 50 or 200 microg/kg, s.c. of (+)8-OH-DPAT vs. (+/-)8-OH-DPAT in ovariectomized rats that were treated with oil or beta-estradiol 3-benzoate (10 microg/day, s.c.) for 2 days. (+)8-OH-DPAT and (+/-)8-OH-DPAT produced a similar magnitude of increase in plasma levels of ACTH and oxytocin. Treatment with beta-estradiol 3-benzoate produced a significant and comparable reduction in the oxytocin response to the highest dose (200 microg/kg, s.c.) of both (+)8-OH-DPAT and (+/-)8-OH-DPAT but did not alter the ACTH response to either (+)8-OH-DPAT or (+/-)8-OH-DPAT. In the dose-response experiment, a dose of 50 microg/kg of (+)8-OH-DPAT produced a maximal increase in plasma levels of ACTH, while the maximal oxytocin response was achieved with a dose of 200 microg/kg, s.c. Treatment with beta-estradiol 3-benzoate reduced the maximal oxytocin response to (+)8-OH-DPAT (by 29%) but did not alter the ACTH response to any doses of (+)8-OH-DPAT. To examine potential mechanisms mediating the effects of estrogen on 5-HT(1A) receptor signaling, we measured the levels of Galpha(i), Galpha(o) and Galpha(z) proteins, which couple 5-HT(1A) receptors to their effector enzymes, in two subregions of the hypothalamus. The levels of Galpha(z) protein were reduced in the mediobasal hypothalamus (containing the ventromedial and arcuate nuclei), which mainly expresses estrogen receptor-alpha, but not in the paraventricular hypothalamus, which mainly expresses estrogen receptor-beta. Estradiol reduced the levels of Galpha(i2) and Galpha(i3 )proteins in both hypothalamic regions but did not affect Galpha(i1) levels in either area. Combined, the data suggest that racemic and stereoselective 8-OH-DPAT have similar neuroendocrine effects and that both estrogen receptor-alpha and estrogen receptor-beta mediate the reduction in levels of Galpha(i2,3) proteins.
本研究检测了雌二醇对雌性大鼠下丘脑5-羟色胺-1A(5-HT(1A))受体信号传导的影响。我们首先检测了单次注射5-HT(1A)受体激动剂(+/-)8-羟基二丙胺基四氢萘((+/-)8-OH-DPAT)(断头前5、15或30分钟)的时间进程效应,以及(+)8-OH-DPAT(50、100、200或500微克/千克,皮下注射)对去卵巢大鼠血浆激素的剂量反应,这些大鼠连续2天每天皮下注射3-苯甲酸雌二醇(10微克/天)或溶剂(芝麻油)。在注射溶剂和雌激素的大鼠中,激素的峰值反应在注射后15分钟出现,并且催产素和促肾上腺皮质激素(ACTH)对注射8-OH-DPAT的反应时间进程具有可比性。然而,只有雌激素处理降低了催产素反应。第二项实验比较了去卵巢大鼠中ACTH和催产素对皮下注射剂量为50或200微克/千克的(+)8-OH-DPAT与(+/-)8-OH-DPAT的反应,这些大鼠连续2天用芝麻油或3-苯甲酸雌二醇(10微克/天,皮下注射)处理。(+)8-OH-DPAT和(+/-)8-OH-DPAT使血浆ACTH和催产素水平升高的幅度相似。3-苯甲酸雌二醇处理使催产素对最高剂量(200微克/千克,皮下注射)的(+)8-OH-DPAT和(+/-)8-OH-DPAT的反应显著且相当程度地降低,但未改变ACTH对(+)8-OH-DPAT或(+/-)8-OH-DPAT的反应。在剂量反应实验中,50微克/千克的(+)8-OH-DPAT剂量使血浆ACTH水平达到最大升高,而皮下注射200微克/千克剂量时催产素反应达到最大。3-苯甲酸雌二醇处理降低了催产素对(+)8-OH-DPAT的最大反应(降低29%),但未改变ACTH对任何剂量(+)8-OH-DPAT的反应。为了检测介导雌激素对5-HT(1A)受体信号传导影响的潜在机制,我们测量了下丘脑两个亚区域中Gα(i)、Gα(o)和Gα(z)蛋白的水平,这些蛋白将5-HT(1A)受体与其效应酶偶联。Gα(z)蛋白水平在下丘脑中间基底部(包含腹内侧核和弓状核)降低,该区域主要表达雌激素受体α,但在主要表达雌激素受体β的室旁下丘脑中未降低。雌二醇降低了两个下丘脑区域中Gα(i2)和Gα(i3)蛋白的水平,但未影响任一区域中Gα(i1)的水平。综合来看,数据表明外消旋和立体选择性的8-OH-DPAT具有相似的神经内分泌效应,并且雌激素受体α和雌激素受体β均介导Gα(i2,3)蛋白水平的降低。